Vertex Pharmaceuticals (VRTX)

AI-powered earnings call analysis for Vertex Pharmaceuticals. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

15 episodes 5 languages

Next Episode

Vertex Pharmaceuticals earnings call scheduled for Nov 2, 2026 (after market close)

New episode expected Nov 3, 2026

Latest Episode

Q2 2026 Earnings

6:42 • 8/13/2026

Vertex Pharmaceuticals (VRTX) - Q2 2026

0:00

6:42

Speed:

Q2 2026 Earnings

9:34 • 2026/8/13

Vertex Pharmaceuticals (VRTX) - Q2 2026

0:00

9:34

Speed:

Q2 2026 Earnings

9:06 • 13/08/2026

Vertex Pharmaceuticals (VRTX) - Q2 2026

0:00

9:06

Speed:

Q2 2026 Earnings

11:21 • 13/8/2026

Vertex Pharmaceuticals (VRTX) - Q2 2026

0:00

11:21

Speed:

Q2 2026 Earnings

7:44 • 13.8.2026

Vertex Pharmaceuticals (VRTX) - Q2 2026

0:00

7:44

Speed:

All Episodes

EN - English (3) CN - 中文 (3) FR - Français (3) ES - Español (3) DE - Deutsch (3)

Q2 2026 Earnings

6:42

Vertex delivered strong Q2 2026 with $3.3B revenue (+12% YoY) and raised FY2026 guidance to $13.1-13.2B, driven by CF leadership, growing CASGEVY and JOURNAVX momentum, and Povi's FDA acceptance for IgAN.

Q1 2026 Earnings

7:46

Vertex achieved strong Q1 2026 results with $2.99B revenue (+8% YoY) and $4.47 adjusted EPS, driven by CF leadership and rapid commercial uptake of new therapies KASJEVY and GERNAVICS, while povitacicept demonstrated compelling Phase III IgAN efficacy with fastest BLA filing in company history.